ВОЗРАСТНЫЕ ОСРОБЕННОСТИ БОЛЕЗНИ ПАРКИНСОНА
Ключевые слова:
Болезнь Паркинсона, возраст, моторные и немоторные нарушенияАннотация
В статье анализируется научная литература по возрастным особенностям болезни Паркинсона. Представлены результаты анализа научной литературы о возникновении двигательных и недвигательных расстройств при ранней форме болезни Паркинсона (РФБП) и поздней форме болезни Паркинсона (ПФБП), а также особенности клинического течения и принципы лечения.
Библиографические ссылки
Катунина Е.А., Залялова З.А., Похабов Д.В., Иванова М.З., Семенова А.М.
Болезнь Паркинсона. Фокус на ранние стадии // Неврология, нейропсихиатри, психосоматика. 2023;15(3):95-103.
DK Khaydarova, HZ Davronova. Cognitive deficit in stage ii cerebrovascular accident in patients with Рarkinson's syndrome. Global research and academic innovations. 2026/3/6. Р.201-204
Khodjieva D. T., Khaydarova D. K., Khaydarov N. K. Diagnosis and treatment of early stage parkinson's disease. European Journal of Research. 2017. P. 43-52
Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson’s disease //Lancet Neurol., 2020.- Vol. 19, P. 170–178.
Camerucci E. et al. Early-Onset Parkinsonism and Early-Onset Parkinson's Disease: A Population-Based Study (2010–2015) // J Parkinsons Disosders, 2021;11(3): P. 1197-1207.
Chaudhary, S. Joshi, D. Pathak, A. Comparison of cognitive profile in young- and late-onset Parkinson's disease patients // Ann. Indian Acad. Neurol. 2018; 21:P. 130-132.
Deng, H. Wang, P. J. Jankovic. The genetics of Parkinson disease Ageing Res. Rev. 2018; 42:72-85.
Espay AJ, Morgante F, Merola A, Fasano A, Marsili L, Fox SH, Bezard E, Picconi B, Calabresi P, Lang AE. Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts // Ann Neurol. 2018. – Vol.84. - P. 797–811.
Fardin N, Homa S., Nazanin R., Maryam at all. Global prevalence and incidence of Young Onset Parkinson’s disease: A systematic review and meta-analysis // Journal of Clinical Neuroscience, 2024.- Volume 125.-P. 59-67.
Foltynie, T. ∙ Bruno, V. ∙ Fox, S. Medical, surgical, and physical treatments for Parkinson's disease // Lancet. 2024; 403:305-324.
Jincheng Ma, Mimi Li, Zhendong Lei The interplay between obesity and triglyceride-glucose index in modulating Parkinson's disease risk: A cross-sectional NHANES study of middle-aged and young adults // Parkinsonism Relat Disorders, 2025 Nov:140:108070.
Hyeyoung P., Bastiaan R., Beomseok J. Amantadine: a first option for symptomatic relief in young-onset Parkinson's disease? // Parkinsonism & Related Disorders, 2026.- Vol. 144. Doi: 10.1016/j.parkreldis.2026.108215.
Karolina P.D. Mubasher A. Q., Cristian F.P. Recognition and characterising non-motor profile in early onset Parkinson's disease (EOPD) // parkinsonism and related disorders journal, 2024.- Vol.129- P. 107-123.
Kim, A. Kim, Y.E. Yun, J.Y. Amantadine and the risk of dyskinesia in patients with early Parkinson's disease: an open-label, pragmatic trial // J. Mov. Disord. 2018; 11:65-71.
Lionnet A, Leclair-Visonneau L, Neunlist M, et al. Does Parkinson’s disease start in the gut? Acta Neuropathol. 2018 Jan;135(1):1-12.
Latella, D. Maggio, M.G. Maresca, G. Impulse control disorders in Parkinson's disease: a systematic review on risk factors and pathophysiology // J. Neurol. Sci. 2019; 398:101-106.
Lunati A, Lesage S, Brice A. The genetic landscape of Parkinson’s disease. Rev Neurol (Paris). 2018 Nov;174(9):628-43.
Marinus J, Zhu K, Marras C, Aarsland D, van Hilten JJ (2018) Risk factors for non-motor symptoms in Parkinson’s disease // Lancet Neurol. 2018.- Vol. 17.- P. 559–568.
McKinley J.E. et al. Neurologic conditions: Parkinson disease // Pubmed. 2019 Feb: 477:16-21.
Mehanna, R. Smilowska, K. Fleisher, J., D. Movement Disorder Society Task Force on Early Onset Parkinson's Age cutoff for early-onset Parkinson's disease: recommendations from the international Parkinson and movement disorder society task force on early onset Parkinson's disease Mov Disord Clin Pract. 2022; 9 (7):869-878.
Mehanna R. et al. Young-onset Parkinson's disease: Its unique features and their impact on quality of life // Parkinsonism Relat Disorders, 2019.- Volume 65. – P. 39-48.
Mullin RL, Chaudhuri KR, Andrews TC, Martin A, Gay S, White CM A study investigating the experience of working for people with Parkinson’s and the factors that influence workplace success // Disabil Rehabil, 2018. – Vol.40. -P. 2032–2039.
Park, S. Shin, J.H. Jeon, S.H. Investigation of the long-term effects of amantadine use in Parkinson's disease // J. Mov. Disord. 2023; 16:224-226.
Post B. et al. Young Onset Parkinson's Disease: A Modern and Tailored // Approach J Parkinsons Disorders, 2020.- P. 29-36.
Postuma, R.B. Poewe, W.Litvan, I. Validation of the MDS clinical diagnostic
criteria for Parkinson's disease // Mov. Disord. 2018; 33.- P. 1601-1608.
Rektorova I., Current treatment of behavioral and cognitive symptoms of Parkinson's disease // Parkinsonism and Related Disorders, 2019. -Volume 59. – P. 65-73.
Rizek P. et al. An update on the diagnosis and treatment of Parkinson disease // CMAJ November 01, 2016 188 (16) 1157-1165; Doi: https://doi.org/10.1503/cmaj.151179.
Stokholm MG, Danielsen EH, Hamilton-Dutoit SJ, Borghammer P.Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Ann Neurol. 2016 Jun;79(6):940-949.
Suzanne Craft Insulin and neurodegenerative disease: shared and specific mechanisms // Parkinsnism and related disorders yournal, 2014 Volume 3, Issue 3, P. 169-178.
Tysnes O.B, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm (Vienna). 2017 Aug;124(8). – P. 901-905.
Titova, N. Chaudhuri, K.R. Personalized medicine and nonmotor symptoms in Parkinson's disease // Int. Rev. Neurobiol. 2017; 134:1257-1281.
Tran T.N. et al. The effect of Non-Motor symptoms on Health-Related quality of life in patients with young onset Parkinson’s Disease: A single center Vietnamese Cross-Sectional study // Clin Park Relat Disorders, 2021, 24;5:100118.
Tolosa E. et al. Challenges in the diagnosis of Parkinson's disease // The Lancet
Neurology, 2021.- Volume 20. - P. 385-397.
Tommasso S., Giulia D.,Giulia M. and all . Young-onset and late-onset Parkinson's disease exhibit a different profile of fluid biomarkers and clinical features // Neurobiology of Aging, 2020.- Volume 90.- P. 119-124.
Verschuur CVM, Suwijn SR, Boel JA, Post B, Bloem BR, van Hilten JJ, van Laar T, Tissingh G, Munts AG, Deuschl G, Lang AE, Dijkgraaf MGW, de Haan RJ, de Bie RMA, LEAP Study Group. Randomized delayed-start trial of levodopa in Parkinson’s disease // N Engl J Med, 2019. – Vol.38.- P. 315–324.
Verschuur, C.V.M. ∙ Suwijn, S.R. ∙ Boel, J.A. Randomized delayed-start trial of levodopa in Parkinson's disease // N. Engl. J. Med. 2019; 380:315-324.
Wanneveich, M. Moisan, F. Jacqmin-Gadda, H. Projections of prevalence, lifetime risk, and life expectancy of Parkinson's disease (2010-2030) in France // Mov. Disord. 2018; 33:1449-1455.
Wang, C.C. Wu, T.L. Lin, F.J. Amantadine treatment and delayed onset of levodopa-induced dyskinesia in patients with early Parkinson's disease // Eur. J. Neurol. 2022; 29(4):1044-1055.
Yang W. et al. Current and projected future economic burden of Parkinson's disease in the U.S // NPJ Parkinsons Dis. 2020; 6:15. P. 1-8.
Ylikotila, P. Tiirikka, T. Moilanen, J.S. Epidemiology of early-onset Parkinson's disease in Finland Parkinsonism Relat Disord. 2015; 21(8):938-942.
Young C, Phillips R, Ebenezer L, Zutt R, Peall K.J. Management of Parkinson’s disease during pregnancy: Literature review and multidisciplinary input // Mov Disord Clin Pract, 2020. -Vol.7.-P. 419–430.
Zhang, J.F. Wang, X.X. Feng, Y. Impulse control disorders in Parkinson's disease: epidemiology, pathogenesis and therapeutic strategies // Front. Psychiatr. 2021; 12, 635494.
